PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-202033	N-[trans-3-[4-Cyano-3-(trifluoromethyl)phenoxy]-2,2,4,4-tetramethylcyclobutyl]-4-[4-[[1-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-4-piperidinyl]methyl]-1-piperazinyl]benzamide	2756443-08-8	CRBN	AR	Inquiry
Molecular Weight: 853.94 Molecular Formula: C46H50F3N7O6 Boiling Point: 986.1±65.0°C at 760 Torr Density: 1.40±0.1 g/cm3 Description: It is a potent and orally bioavailable proteolysis targeting chimera degrader of androgen receptor for the treatment of prostate cancer.
	BPL-202034	N-[trans-3-[[6-Cyano-5-(trifluoromethyl)-3-pyridinyl]oxy]-2,2,4,4-tetramethylcyclobutyl]-4-[4-[[1-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-4-piperidinyl]methyl]-1-piperazinyl]benzamide	2756443-09-9	CRBN	AR	Inquiry
Molecular Weight: 854.93 Molecular Formula: C45H49F3N8O6 Boiling Point: 1002.8±65.0°C at 760 Torr Density: 1.42±0.1 g/cm3 Description: It is a potent and orally bioavailable proteolysis targeting chimera degrader of androgen receptor for the treatment of prostate cancer.
	BPL-202035	(2S,4R)-1-((S)-2-(tert-Butyl)-17-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,16-dioxo-6,12-dioxa-3,15-diazaheptadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	2683008-35-5	VHL	BRD2 BRD3 BRD4	Inquiry
Molecular Weight: 1000.69 Molecular Formula: C50H62ClN9O7S2 Density: 1.37±0.1 g/cm3 Description: It is an amide-to-ester-substituted, VHL-based BET degrader that improves permeability and bioactivity.
	BPL-202036	(2S,4R)-1-((S)-2-(tert-Butyl)-15-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-4,14-dioxo-6,10-dioxa-3,13-diazapentadecanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	2086299-73-0	VHL	BRD2 BRD3 BRD4	Inquiry
Molecular Weight: 972.64 Molecular Formula: C48H58ClN9O7S2 Density: 1.40±0.1 g/cm3 Description: It is an amide-to-ester-substituted, VHL-based BET degrader that improves permeability and bioactivity.
	BPL-202037	(S)-13-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidine-1-carbonyl)-14,14-dimethyl-11-oxo-3,6,9-trioxa-12-azapentadecyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate	2683008-36-6	VHL	BRD2 BRD3 BRD4	Inquiry
Molecular Weight: 1003.65 Molecular Formula: C49H59ClN8O9S2 Density: 1.39±0.1 g/cm3 Description: It is an amide-to-ester-substituted, VHL-based BET degrader that improves permeability and bioactivity.
	BPL-202038	2-((5-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)pentyl)oxy)ethyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate	2683008-38-8	VHL	BRD2 BRD3 BRD4	Inquiry
Molecular Weight: 1001.67 Molecular Formula: C50H61ClN8O8S2 Density: 1.37±0.1 g/cm3 Description: It is an amide-to-ester-substituted, VHL-based BET degrader that improves permeability and bioactivity.
	BPL-202039	2-(3-(2-(((S)-1-((2S,4R)-4-Hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)propoxy)ethyl 2-((S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate	2683008-39-9	VHL	BRD2 BRD3 BRD4	Inquiry
Molecular Weight: 973.62 Molecular Formula: C48H57ClN8O8S2 Density: 1.39±0.1 g/cm3 Description: It is an amide-to-ester-substituted, VHL-based BET degrader that improves permeability and bioactivity.
	BPL-202040	(2S,4S)-4-(14-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinolin-7-yl)oxy)-3,6,9,12-tetraoxatetradecanamido)-1-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)-N-((R)-1-phenylpropyl)pyrrolidine-2-carboxamide	2126803-02-7	IAP	RIPK2	Inquiry
Molecular Weight: 1075.36 Molecular Formula: C54H74N8O11S2 Boiling Point: 1198.5±65.0°C at 760 Torr Density: 1.29±0.1 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202041	(S)-N-((S)-1-(1-(14-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinolin-7-yl)oxy)-3,6,9,12-tetraoxatetradecanoyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2762179-93-9	IAP	RIPK2	Inquiry
Molecular Weight: 1131.39 Molecular Formula: C55H67FN8O11S3 Boiling Point: 1204.4±65.0°C at 760 Torr Density: 1.328±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202042	(S)-7-(2-(2-(2-(2-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)ethoxy)ethoxy)ethoxy)ethoxy)-2-((S)-3,3-dimethyl-2-((S)-2-(methylamino)propanamido)butanoyl)-N-((R)-1,2,3,4-tetrahydronaphthalen-1-yl)-1,2,3,4-tetrahydroisoquinoline-3-carboxamide	2126802-94-4	IAP	RIPK2	Inquiry
Molecular Weight: 1054.32 Molecular Formula: C55H75N9O10S Boiling Point: 1193.9±65.0°C at 760 Torr Density: 1.30±0.1 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202043	(S)-N-((S)-1-(1-(14-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)-3,6,9,12-tetraoxatetradecanoyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2762179-94-0	IAP	RIPK2	Inquiry
Molecular Weight: 1093.31 Molecular Formula: C52H69FN10O11S2 Boiling Point: 1196.0±65.0°C at 760 Torr Density: 1.313±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202044	(S)-N-((S)-1-(1-(2-(4-(((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)methyl)piperidin-1-yl)pyrimidine-5-carbonyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2143956-24-3	IAP	RIPK2	Inquiry
Molecular Weight: 1078.31 Molecular Formula: C53H64FN13O7S2 Density: 1.347±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202045	(S)-N-((S)-1-(1-(2-(4-(2-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)ethyl)piperidin-1-yl)pyrimidine-5-carbonyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2762179-95-1	IAP	RIPK2	Inquiry
Molecular Weight: 1092.34 Molecular Formula: C54H66FN13O7S2 Density: 1.337±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202046	(S)-N-((S)-1-(1-(2-(4-(3-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)piperidin-1-yl)pyrimidine-5-carbonyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2143956-19-6	IAP	RIPK2	Inquiry
Molecular Weight: 1106.36 Molecular Formula: C55H68FN13O7S2 Density: 1.327±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202047	(S)-N-((S)-1-(1-(2-(4-(3-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)piperazin-1-yl)pyrimidine-5-carbonyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2143956-27-6	IAP	RIPK2	Inquiry
Molecular Weight: 1107.35 Molecular Formula: C54H67FN14O7S2 Density: 1.343±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202048	(S)-N-((S)-1-(1-(4-(4-(3-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)piperazin-1-yl)benzoyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2762179-96-2	IAP	RIPK2	Inquiry
Molecular Weight: 1105.38 Molecular Formula: C56H69FN12O7S2 Density: 1.319±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202049	(S)-N-((S)-1-(1-(6-(4-(2-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)ethyl)piperazin-1-yl)nicotinoyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2143956-21-0	IAP	RIPK2	Inquiry
Molecular Weight: 1092.34 Molecular Formula: C54H66FN13O7S2 Density: 1.341±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202050	(S)-N-((S)-1-(1-(6-(4-(3-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)piperazin-1-yl)nicotinoyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2143956-29-8	IAP	RIPK2	Inquiry
Molecular Weight: 1106.36 Molecular Formula: C55H68FN13O7S2 Density: 1.331±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202051	(S)-N-((S)-1-(1-(5-(4-(2-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)ethyl)piperazin-1-yl)pyrazine-2-carbonyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2143956-25-4	IAP	RIPK2	Inquiry
Molecular Weight: 1093.33 Molecular Formula: C53H65FN14O7S2 Density: 1.353±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.
	BPL-202052	(S)-N-((S)-1-(1-(5-(4-(3-((6-(tert-Butylsulfonyl)-4-((4,5-dimethyl-1H-pyrazol-3-yl)amino)quinazolin-7-yl)oxy)propyl)piperazin-1-yl)pyrazine-2-carbonyl)piperidin-4-yl)-2-((S)-2-(4-(4-fluorobenzoyl)thiazol-2-yl)pyrrolidin-1-yl)-2-oxoethyl)-2-(methylamino)propanamide	2143956-26-5	IAP	RIPK2	Inquiry
Molecular Weight: 1107.35 Molecular Formula: C54H67FN14O7S2 Density: 1.343±0.06 g/cm3 Description: It is a potent RIPK2 PROTAC with attractive pharmacokinetic profiles.